Results 51 to 60 of about 1,579,650 (291)

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

open access: yesMolecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test

open access: yesDiagnostic Pathology, 2022
Background The expression of PD-L1 in the immune microenvironment can guide the application of immunosuppressants. In order to monitor the immune status of the body, repeated biopsies have to be taken.
Keyu Yuan   +7 more
doaj   +1 more source

Sex-dependent expression and release of PD-L1 by human endothelial cells

open access: yes, 2022
noneI checkpoint immunitari sono una classe di molecole che regola negativamente l’infiammazione, trasducendo segnali inibitori per le cellule del sistema immunitario.
MESTRINER, MAURO
core  

DataSheet_1_Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1.pdf

open access: yes, 2023
BackgroundGalectin-3 (Gal-3) is a β-galactoside-binding lectin that is highly expressed within the tumor microenvironment of aggressive cancers and has been suggested to predict a poor response to immune checkpoint therapy with the anti-PD-1 monoclonal ...
James A. Roper   +17 more
core   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

Extracellular vesicles mediate intercellular transfer of PD-L1 and bystander T-cell suppression

open access: yesCellular and Molecular Life Sciences
Extracellular vesicles (EVs) carrying programmed death-ligand 1(PD-L1) on their membranes regulate immune responses. While membrane PD-L1 can be exchanged between tumor and immune cells through immune synapse, it remains unclear whether PD-L1 exchange ...
Amar Yeware   +4 more
doaj   +1 more source

Pioneering of Antibody-Assisted Structure-Based Drug Discovery for PD-L1

open access: yes, 2023
The principle of antibody-assisted drug discovery aims to use a diverse panel of single domain antibodies (VHH) to identify rare conformational states and/or novel allosteric sites that could modulate function, which may facilitate the discovery of new ...
Tara Kang-Pettinger (15905717)
core   +1 more source

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma

open access: yesMolecular Oncology, EarlyView.
Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach   +9 more
wiley   +1 more source

Real-World Survival Outcomes Following Chemoradiotherapy with or Without Durvalumab in PD-L1-Defined Subgroups of Stage III Unresectable NSCLC

open access: yesCurrent Oncology
Durvalumab consolidation after definitive chemoradiotherapy (CRT) is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC) but real-world data comparing PD-L1-defined subgroups are limited.
Janne Selke   +7 more
doaj   +1 more source

Programmed Death-Ligand 1 Expression in Lymphovascular Tumor Emboli in Lung Cancer

open access: yesJTO Clinical and Research Reports, 2022
Introduction: Programmed death-ligand 1 (PD-L1) expression determined by immunohistochemistry is the most widely used biomarker for predicting response to immune checkpoint inhibitors.
Yi-Chen Yeh, MD   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy